(CGC) Canopy Growth - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 449m USD | Total Return: 6.6% in 12m

Cannabis, Hemp, Edibles, Vapes
Total Rating 17
Safety 36
Buy Signal -1.02
Drug Manufacturers - Specialty & Generic
Industry Rotation: -0.8
Market Cap: 449M
Avg Turnover: 6.18M USD
ATR: 6.35%
Peers RS (IBD): 20.1
Risk 5d forecast
Volatility101%
Rel. Tail Risk-22.7%
Reward TTM
Sharpe Ratio0.56
Alpha-13.50
Character TTM
Beta0.701
Beta Downside-0.066
Drawdowns 3y
Max DD95.10%
CAGR/Max DD-0.63
EPS (Earnings per Share) EPS (Earnings per Share) of CGC over the last years for every Quarter: "2021-03": -1.85, "2021-06": 0.84, "2021-09": -0.03, "2021-12": -0.28, "2022-03": -1.46, "2022-06": -0.89, "2022-09": -0.47, "2022-12": -0.54, "2023-03": -1.28, "2023-06": -0.07, "2023-09": -0.43, "2023-12": -2.62, "2024-03": -1.03, "2024-06": -1.6, "2024-09": -1.06, "2024-12": -1.0608, "2025-03": -1.43, "2025-06": -0.1932, "2025-09": -0.01, "2025-12": -0.18, "2026-03": 0,
EPS CAGR: 11.30%
EPS Trend: 29.0%
Last SUE: 0.07
Qual. Beats: 0
Revenue Revenue of CGC over the last years for every Quarter: 2021-03: 148.439, 2021-06: 136.209, 2021-09: 131.374, 2021-12: 140.972, 2022-03: 111.77, 2022-06: 105.92, 2022-09: 87.941, 2022-12: 84.85, 2023-03: 73.713, 2023-06: 76.258, 2023-09: 69.595, 2023-12: 78.505, 2024-03: 72.788, 2024-06: 66.212, 2024-09: 62.991, 2024-12: 74.761, 2025-03: 65.031, 2025-06: 72.134, 2025-09: 66.683, 2025-12: 74.541, 2026-03: null,
Rev. CAGR: -10.24%
Rev. Trend: -76.0%
Last SUE: 0.18
Qual. Beats: 0

Warnings

Share dilution 213.3% YoY - potential capital distress

Interest Coverage Ratio -6.9 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: CGC Canopy Growth

Canopy Growth Corporation (CGC) produces and sells cannabis, hemp, and related products in Canada, Germany, and Australia. The company operates in four segments: Canada Cannabis, International Markets Cannabis, Storz & Bickel, and This Works.

CGC offers a variety of cannabis products, including dried flower, pre-rolled joints, extracts, edibles, vapes, and oils. The company markets these products under multiple brands. The cannabis industry is subject to evolving regulations across different jurisdictions.

CGC is headquartered in Smiths Falls, Canada. Consider exploring ValueRay for a deeper dive into CGCs financials and market performance.

Headlines to Watch Out For
  • Canadian recreational cannabis sales growth impacts revenue
  • German medical cannabis market expansion boosts international sales
  • Storz & Bickel vaporizer sales drive segment performance
  • Regulatory changes in key markets pose significant risk
  • Cash burn rate and profitability remain critical investor concerns
Piotroski VR‑10 (Strict) 1.0
Net Income: -326.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.08 > 0.02 and ΔFCF/TA 6.15 > 1.0
NWC/Revenue: 153.2% < 20% (prev 88.19%; Δ 64.97% < -1%)
CFO/TA -0.07 > 3% & CFO -78.7m > Net Income -326.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.34 > 1.5 & < 3
Outstanding Shares: last quarter (345.5m) vs 12m ago 213.3% < -2%
Gross Margin: 25.85% > 18% (prev 0.31%; Δ 2.55k% > 0.5%)
Asset Turnover: 24.52% > 50% (prev 23.77%; Δ 0.75% > 0%)
Interest Coverage Ratio: -6.90 > 6 (EBITDA TTM -245.5m / Interest Expense TTM 41.3m)
Altman Z'' -15.00
A: 0.39 (Total Current Assets 524.7m - Total Current Liabilities 98.3m) / Total Assets 1.11b
B: -9.97 (Retained Earnings -11.03b / Total Assets 1.11b)
C: -0.25 (EBIT TTM -284.8m / Avg Total Assets 1.14b)
D: -5.34 (Book Value of Equity -1.86b / Total Liabilities 348.0m)
Altman-Z'' Score: -37.28 = D
Beneish M -3.61
DSRI: 0.66 (Receivables 32.5m/49.1m, Revenue 278.4m/276.8m)
GMI: 1.18 (GM 25.85% / 30.51%)
AQI: 0.60 (AQ_t 0.27 / AQ_t-1 0.45)
SGI: 1.01 (Revenue 278.4m / 276.8m)
TATA: -0.22 (NI -326.6m - CFO -78.7m) / TA 1.11b)
Beneish M-Score: -3.61 (Cap -4..+1) = AAA
What is the price of CGC shares? As of April 08, 2026, the stock is trading at USD 0.99 with a total of 3,447,837 shares traded.
Over the past week, the price has changed by +4.54%, over one month by -7.28%, over three months by -16.63% and over the past year by +6.56%.
Is CGC a buy, sell or hold? Canopy Growth has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell CGC.
  • StrongBuy: 0
  • Buy: 2
  • Hold: 4
  • Sell: 1
  • StrongSell: 3
What are the forecasts/targets for the CGC price?
Analysts Target Price 1.8 77.8%
Canopy Growth (CGC) - Fundamental Data Overview as of 07 April 2026
Market Cap CAD = 625.0m (449.1m USD * 1.3918 USD.CAD)
P/E Forward = 20.3666
P/S = 1.6131
P/B = 0.7754
Revenue TTM = 278.4m CAD
EBIT TTM = -284.8m CAD
EBITDA TTM = -245.5m CAD
Long Term Debt = 225.0m CAD (from longTermDebt, last quarter)
Short Term Debt = 12.9m CAD (from shortTermDebt, last quarter)
Debt = 255.1m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.2m CAD (from netDebt column, last quarter)
Enterprise Value = 508.8m CAD (625.0m + Debt 255.1m - CCE 371.3m)
Interest Coverage Ratio = -6.90 (Ebit TTM -284.8m / Interest Expense TTM 41.3m)
EV/FCF = -5.87x (Enterprise Value 508.8m / FCF TTM -86.7m)
FCF Yield = -17.04% (FCF TTM -86.7m / Enterprise Value 508.8m)
FCF Margin = -31.14% (FCF TTM -86.7m / Revenue TTM 278.4m)
Net Margin = -117.3% (Net Income TTM -326.6m / Revenue TTM 278.4m)
Gross Margin = 25.85% ((Revenue TTM 278.4m - Cost of Revenue TTM 206.4m) / Revenue TTM)
Gross Margin QoQ = 28.80% (prev 32.85%)
Tobins Q-Ratio = 0.46 (Enterprise Value 508.8m / Total Assets 1.11b)
Interest Expense / Debt = 2.88% (Interest Expense 7.34m / Debt 255.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -225.0m (EBIT -284.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.34 (Total Current Assets 524.7m / Total Current Liabilities 98.3m)
Debt / Equity = 0.34 (Debt 255.1m / totalStockholderEquity, last quarter 758.2m)
 Debt / EBITDA = 0.47 (negative EBITDA) (Net Debt -116.2m / EBITDA -245.5m)
 Debt / FCF = 1.34 (negative FCF - burning cash) (Net Debt -116.2m / FCF TTM -86.7m)
 Total Stockholder Equity = 617.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.77% (Net Income -326.6m / Total Assets 1.11b)
RoE = -52.88% (Net Income TTM -326.6m / Total Stockholder Equity 617.6m)
RoCE = -33.80% (EBIT -284.8m / Capital Employed (Equity 617.6m + L.T.Debt 225.0m))
 RoIC = -25.55% (negative operating profit) (NOPAT -225.0m / Invested Capital 880.7m)
 WACC = 6.66% (E(625.0m)/V(880.2m) * Re(8.45%) + D(255.1m)/V(880.2m) * Rd(2.88%) * (1-Tc(0.21)))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 104.1%
 [DCF] Fair Price = unknown (Cash Flow -86.7m)
 EPS Correlation: 28.97 | EPS CAGR: 11.30% | SUE: 0.07 | # QB: 0
Revenue Correlation: -75.98 | Revenue CAGR: -10.24% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.10 | Chg7d=-0.095 | Chg30d=-0.095 | Revisions Net=+0 | Analysts=2
EPS next Year (2027-03-31): EPS=-0.29 | Chg7d=-0.057 | Chg30d=-0.135 | Revisions Net=+0 | Growth EPS=+40.7% | Growth Revenue=+27.2%
External Resources
Dataroma Stockcircle